Citius Oncology Secures \$36.5 Million in Financing to Accelerate LYMPHIR® Commercialization
Citius Oncology Secures \$36.5 Million in Financing to Accelerate LYMPHIR® Commercialization
Key Highlights
- Total Capital Raised: Up to \$36.5 million through a mix of debt and equity financing.
- Debt Facility: Avenue Capital Group to provide up to \$25 million via a senior secured credit facility, with an initial \$10 million funded at closing and up to \$15 million in additional tranches subject to revenue and liquidity milestones.
- Warrant Exercise: Concurrent gross proceeds of approximately \$11.5 million from the immediate exercise of outstanding warrants by a single healthcare-focused institutional investor.
- Purpose: Financing to support the commercialization of LYMPHIR® (denileukin diftitox-cxdl), working capital, and general corporate purposes while preserving flexibility for future growth.
- Warrants and Conversion Rights: Issuance of substantial new warrants and the possibility for Avenue Capital to convert up to \$4 million of the loan into equity at a premium.
- Potential Share Dilution: Large number of new warrants and amendments to existing warrants at a reduced exercise price, which could result in dilution of existing shareholders.
- Product Update: Details on LYMPHIR’s FDA approval, its commercial launch, market potential, and strategic importance.
Detailed Breakdown
Debt Financing from Avenue Capital Group
Citius Oncology, Inc. (Nasdaq: CTOR), a specialty biopharmaceutical company focused on novel targeted oncology therapies, announced it has secured a senior secured term loan credit facility with Avenue Venture Opportunities Fund II, L.P., a fund of Avenue Capital Group. The facility provides up to \$25 million in capital, structured as follows:
- Initial Tranche: \$10 million funded immediately at closing.
- Additional Tranches: Up to \$15 million subject to the company achieving specific revenue and liquidity milestones.
- Term: 3.5 years.
- Warrants: Avenue receives warrants to purchase up to 11,111,111 shares at \$0.90/share, exercisable for five years after shareholder approval. Additional warrants covering 10% of any future tranche amount (divided by \$0.90/share) will also be issued if further funds are drawn.
- Conversion Option: Avenue has the right to convert up to \$4 million of the outstanding principal into shares at a 20% premium to the warrant exercise price, subject to certain conditions.
Equity Financing via Warrant Exercise
Simultaneously, Citius Oncology entered into an agreement with a single healthcare-focused institutional investor for the immediate exercise of outstanding warrants. Key points include:
- Gross Proceeds: Approximately \$11.5 million (before placement agent fees and expenses).
- Warrant Details: Exercise of up to 12,777,778 shares at a reduced exercise price of \$0.90/share.
- New Warrants: Issuance of new unregistered warrants to purchase up to 25,555,556 shares at \$0.90/share, exercisable after shareholder approval, expiring five years after the later of approval or the effective date of the resale registration statement.
- Amendment of Existing Warrants: Warrants to purchase up to 15,697,024 shares (originally issued at \$1.09/share) are amended to a \$0.90 exercise price, with a new five-year term.
Note: The substantial issuance and amendment of warrants at a reduced exercise price has the potential to significantly dilute existing shareholders.
Use of Proceeds
The company intends to use the net proceeds primarily to:
- Expand the sales force.
- Enhance market access initiatives.
- Support medical affairs activities.
- Strengthen manufacturing and supply chain.
- General working capital and corporate purposes.
Product and Market Update: LYMPHIR®
LYMPHIR® (denileukin diftitox-cxdl) is a targeted immune therapy approved by the FDA for adults with relapsed or refractory Stage I-III cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy. The product is a recombinant fusion protein targeting IL-2 receptors and exerts its effect through diphtheria toxin-mediated inhibition of protein synthesis, leading to tumor cell death.
- U.S. Market Opportunity: Estimated to exceed \$400 million, with significant growth potential and unmet needs.
- Intellectual Property: Orphan drug designation, complex technology, trade secrets, and pending patents, including combination therapy with checkpoint inhibitors.
- Commercial Launch: U.S. launch occurred in December 2025.
- Regulatory Status: Previously approved in Japan for CTCL and PTCL; Citius holds global rights excluding India, Japan, and certain Asian regions.
Strategic and Financial Implications
- Shareholder Dilution: The issuance of significant new and amended warrants at \$0.90/share may result in considerable dilution of existing shareholders if exercised.
- Financial Flexibility: The combined financings provide ample runway to drive LYMPHIR’s commercial execution and position the company for future growth initiatives.
- Validation from Avenue Capital: Avenue’s participation and the structure of the deal underscore confidence in Citius Oncology’s commercial trajectory and the long-term potential of LYMPHIR.
- Milestone-Linked Funding: Future access to up to \$15 million is dependent on achieving predefined revenue and liquidity milestones, linking capital access to commercial performance.
- Potential for Further News Flow: Progress in commercial uptake, achievement of milestones for additional funding, and updates on combination therapy development could act as future share price catalysts.
Additional Information
- Origination and Placement: H.C. Wainwright & Co. acted as exclusive agent for the financings.
- Resale Registration: The company has agreed to file a registration statement with the SEC to allow resale of shares issuable upon exercise of the new warrants.
- Risk Factors: The company’s forward-looking statements note multiple risks, including the need for further funding, successful execution of the commercial strategy, market acceptance, supply chain reliability, and regulatory compliance.
Contact Information
Disclaimer
This article is for informational purposes only and does not constitute investment advice, an offer, or a solicitation to buy or sell any securities. Investors should conduct their own research and consult with a qualified financial advisor before making any investment decisions. The information herein is based on public disclosures by Citius Oncology, Inc. and may contain forward-looking statements subject to risks and uncertainties. Actual results may differ materially from those projected. The author and publisher assume no liability for any losses incurred based on this article.
View CITIUS ONCOLOGY, INC. Historical chart here
